European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/11/2026

1. ORCL
2. ADBE
3. RH
4. SPY
5. CPRT
6. ACVA
7. SEDG
8. PMTS
9. QQQ
10. TENB

Go back to European Commission Approves KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
Merck & Co. (NYSE: MRK) Delayed: 143.93 -0.78 (0.54%)
Previous Close $144.71    52 Week High $65.46 
Open $145.52    52 Week Low $47.97 
Day High $145.90    P/E 97.91 
Day Low $143.68    EPS $1.47 
Volume 8,623,288